Richard H. Scott

Richard H. Scott

Auto-generated profile, based on publicly available information

Richard H. Scott

Genomics England Ltd, Level 21 One Canada Square, London, United Kingdom

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 June 2023 in Nature Reviews Genetics
Verified
Journal Article
Closed access
PDF file
ZSZornitza Stark
Zornitza Stark
RSRichard H. Scott
Richard H. Scott

7 October 2024 in Nature Reviews Genetics
Verified
Journal Article
Open access
PDF file
ZSZornitza Stark
Zornitza Stark
DGDavid Glazer
David Glazer
OHOliver Hofmann
Oliver Hofmann
ARAugusto Rendon
Augusto Rendon
CMChristian R. Marshall
Christian R. Marshall
RSRichard H. Scott
Richard H. Scott
Genomic data from millions of individuals have been generated worldwide to drive discovery and clinical impact in precision medicine. Lowering the barriers to using these data collectively is needed to equitably realize the benefits of the diversity and scale of population data. We examine the current landscape of global genomic data sharing, including the evolution of data sharing models from data aggregation through to data visiting, and for certain use cases, cross-cohort analysis using federated approaches across multiple environments. We highlight emerging examples of best practice relating to participant, patient and community engagement; evolution of technical standards, tools and infrastructure; and impact of research and health-care policy. We outline 12 actions we can all take together to scale up efforts to enable safe global data sharing and move beyond projects demonstrating feasibility to routinely cross-analysing research and clinical data sets, optimizing benefit.

20 February 2025 in Journal of Clinical Oncology
Verified
Journal Article
Open access
ILIvone U.S. Leong
Ivone U.S. Leong
CCClaudia P. Cabrera
Claudia P. Cabrera
VCValentina Cipriani
Valentina Cipriani
PRPaul J. Ross
Paul J. Ross
RTRichard Turner
Richard Turner
EMEllen M. McDonagh
Ellen M. McDonagh
PURPOSE: As part of the 100,000 Genomes Project, we set out to assess the potential viability and clinical impact of reporting genetic variants associated with drug-induced toxicity for patients with cancer recruited for whole-genome sequencing (WGS) as part of a genomic medicine service. METHODS: Germline WGS from 76,805 participants was analyzed for pharmacogenetic (PGx) variants in four genes ( DPYD , NUDT15 , TPMT , UGT1A1 ) associated with toxicity induced by five drugs used in cancer treatment (capecitabine, fluorouracil, mercaptopurine, thioguanine, irinotecan). Linking genomic data with prescribing and hospital incidence records, a phenome-wide association study (PheWAS) was performed to identify whether phenotypes indicative of adverse drug reactions (ADRs) were enriched in drug-exposed individuals with the relevant PGx variants. In a subset of 7,081 patients with cancer, DPYD variants were reported back to clinicians and outcomes were collected. RESULTS: We identified clinically relevant PGx variants across the four genes in 62.7% of participants in our cohort. Extending this to annual prescription numbers in England for the drugs affected by these PGx variants, approximately 14,540 patients per year could potentially benefit from a reduced dose or alternative drug to reduce the risk of ADRs. Validating PGx associations in a real-world data set, we found a significant association between PGx variants in DPYD and toxicity-related phenotypes in patients treated with capecitabine or fluorouracil. Reported DPYD variants were deemed informative for clinical decision making in a majority of cases. CONCLUSION: Reporting PGx variants from germline WGS relevant to patients with cancer alongside primary findings related to their cancer can be clinically informative, informing prescribing to reduce the risk of ADRs. Extending the range of actionable variants to those found in patients of non-European ancestry is important and will extend the potential clinical impact.

25 July 2022 in Movement Disorders
Verified
Journal Article
Open access
KRKimberley M. Reid
Kimberley M. Reid
RSRobert Spaull
Robert Spaull
SSSmrithi Salian
Smrithi Salian
KBKaty Barwick
Katy Barwick
EMEsther Meyer
Esther Meyer
MKManju A Kurian
Manju A Kurian
Background: Despite advances in next generation sequencing technologies, the identification of variants of uncertain significance (VUS) can often hinder definitive diagnosis in patients with complex neurodevelopmental disorders.Objective: The objective of this study was to identify and characterize the underlying cause of disease in a family with two children with severe developmental delay associated with generalized dystonia and episodic status dystonicus, chorea, epilepsy, and cataracts.Methods: Candidate genes identified by autozygosity mapping and whole‐exome sequencing were characterized using cellular and vertebrate model systems.Results: Homozygous variants were found in three candidate genes: MED27, SLC6A7, and MPPE1. Although the patients had features of MED27‐related disorder, the SLC6A7 and MPPE1 variants were functionally investigated. SLC6A7 variant in vitro overexpression caused decreased proline transport as a result of reduced cell‐surface expression, and zebrafish knockdown of slc6a7 exhibited developmental delay and fragile motor neuron morphology that could not be rescued by L‐proline transporter–G396S RNA. Lastly, patient fibroblasts displayed reduced cell‐surface expression of glycophosphatidylinositol‐anchored proteins linked to MPPE1 dysfunction.Conclusions: We report a family harboring a homozygous MED27 variant with additional loss‐of‐function SLC6A7 and MPPE1 gene variants, which potentially contribute to a blended phenotype caused by multilocus pathogenic variants. © 2022 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society

2 September 2021 in medRxiv
Verified
Preprint
Open access
PDF file
AKAthanasios Kousathanas
Athanasios Kousathanas
EPErola Pairo-Castineira
Erola Pairo-Castineira
KRKonrad Rawlik
Konrad Rawlik
ASAlex Stuckey
Alex Stuckey
COChristopher A Odhams
Christopher A Odhams
TWTimothy Walsh
Timothy Walsh
Critical illness in COVID-19 is caused by inflammatory lung injury, mediated by the host immune system. We and others have shown that host genetic variation influences the development of illness requiring critical care 1 or hospitalisation 2;3;4 following SARS-Co-V2 infection. The GenOMICC (Genetics of Mortality in Critical Care) study recruits critically-ill cases and compares their genomes with population controls in order to find underlying disease mechanisms. Here, we use whole genome sequencing and statistical fine mapping in 7,491 critically-ill cases compared with 48,400 population controls to discover and replicate 22 independent variants that significantly predispose to life-threatening COVID-19. We identify 15 new independent associations with critical COVID-19, including variants within genes involved in interferon signalling ( IL10RB, PLSCR1 ), leucocyte differentiation ( BCL11A ), and blood type antigen secretor status ( FUT2 ). Using transcriptome-wide association and colocalisation to infer the effect of gene expression on disease severity, we find evidence implicating expression of multiple genes, including reduced expression of a membrane flippase ( ATP11A ), and increased mucin expression ( MUC1 ), in critical disease. We show that comparison between critically-ill cases and population controls is highly efficient for genetic association analysis and enables detection of therapeutically-relevant mechanisms of disease. Therapeutic predictions arising from these findings require testing in clinical trials.

7 January 2010 in Familial Cancer
Verified
Journal Article
Closed access
PDF file
FAFatemeh Abbaszadeh
Fatemeh Abbaszadeh
KBKaren T. Barker
Karen T. Barker
CMCarmel McConville
Carmel McConville
RSRichard H. Scott
Richard H. Scott
NRNazneen Rahman
Nazneen Rahman